Delta Variant (B.1.617.2) Update – 14 July 2021 BioGX has been closely surveilling the emergence of new coronavirus variants ensuring its products performance in detecting SARS-CoV-2. The emerging variant known as “delta variant” or B.1.617.2 has been documented globally. Variant B.1.617.2 is considered to be more transmissible than variants B.1.1.7 and B.1.351. BioGX has utilized the GISAID database […]
About Robyn Martin-Schubart
This author has not written his bio yet.
But we are proud to say that Robyn Martin-Schubart contributed 10 entries already.
Entries by Robyn Martin-Schubart
Birmingham, Alabama, July 01, 2021 – BioGX, a global provider of molecular diagnostic solutions, announced that the United States Food and Drug Administration has issued Emergency Use Authorization (EUA) for their breakthrough direct sample addition, Xfree™ COVID-19 test. Xfree COVID-19 is a complete test lyophilized in a single tube, for extraction-free, direct sample addition real-time […]
BIRMINGHAM, ALABAMA, 03 March 2021 – BioGX Sample-Ready™ lyophilized qPCR technology was selected by the NASA WetLab-2 program in 2016 to conduct genetic analysis in a microgravity environment aboard the International Space Station (ISS). Five years and several launches later, the collaboration is still going strong with a track record of success. The International Space […]
Birmingham-based molecular diagnostics company BioGX has purchased a building on Valleydale Road in Shelby County that will house its corporate headquarters and expanded research and development and manufacturing capabilities. The company will progress from its current location at the Innovation Depot and move to the new facility in several phases in 2021, making an investment […]
Californian L452R mutation. As new strains of SARS-CoV-2 are identified across the globe, we will supply an update related to the coverage of BioGX COVID-19 assays. On January 18, 2021, BioGX performed in silico analysis of the primer and probes used for SARS-CoV-2 diagnostics using the N1- and N2-gene regions. A total of 793 SARS-CoV-2 […]
World’s Simplest High-Throughput RT-PCR Test for COVID-19 has the potential to increase testing capacity by millions per week Birmingham, AL, October 12, 2020 – BioGX, a molecular diagnostics solutions company, announced FDA Emergency Use Authorization (EUA) submission of an extraction-free, direct sample addition RT-PCR test for detection of SARS-CoV-2 viral RNA in patients suspected of […]
The BioGX multiplex COVID-19, Flu A, Flu B and RSV test is intended for the qualitative detection of RNA specific to SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus A/B that may be present in Pharyngeal and Nasopharyngeal swab collections in transport media and saline, obtained from individuals at risk of respiratory viral infections. […]
Amsterdam, The Netherlands, 29 September 2020 – BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAX™ System. The test is offered in BioGX’s trusted, easy […]
The American MedTech firm BioGX is supplying coronavirus test kits worldwide from its global office and lab in Amsterdam Science Park. “Everyone is coming together to help, they recognise the importance of mass testing,” CEO Dr Shazi Iqbal explains to I amsterdam how the company is working to fight the global coronavirus outbreak. Full article […]
The past few months has shown that a team’s rapid response to expediting an assay globally, dedicated to the detection of SARS-CoV-2, is possible. BioGX, in a long-term partnership with Becton, Dickinson and Company, has submitted a test to the FDA for emergency use authorisation (EUA) in the US, in parallel to CE-IVD approval. In […]